Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab

Anticancer Drugs. 2005 Jan;16(1):83-5. doi: 10.1097/00001813-200501000-00012.

Abstract

A patient with stage IV non-Hodgkin's lymphoma and chronic hepatitis who was treated with chemotherapy and rituximab developed fatal reactivation of hepatitis B. High viral load titers of hepatitis B DNA were demonstrated. DNA sequencing analysis revealed the presence of the precore mutant strain. Hepatitis B reactivation in patients receiving rituxmab-based chemotherapy is reviewed and the role of precore mutant virus strains resulting in fatal complications is discussed.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Fatal Outcome
  • Hepatitis B / chemically induced*
  • Hepatitis B / virology
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / physiology
  • Humans
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / pathology
  • Male
  • Neoplasm Staging
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Recurrence
  • Rituximab
  • Vincristine / administration & dosage
  • Vincristine / adverse effects
  • Virus Activation / drug effects*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol